New Trial Offers Hope for Advanced Colon Cancer

For individuals facing advanced colon cancer, there might be a new ray of hope. A recent clinical trial has revealed a treatment approach that could significantly extend patient survival, a finding that is particularly crucial given the higher diagnosis and mortality rates of colon cancer among Black Americans.

Promising Results for a New Treatment Combo

The study found that a combination of two experimental immunotherapy drugs, etrumadenant and zimberelimab, when used alongside standard chemotherapy, resulted in a median survival of 19.7 months for patients. This is a significant improvement compared to the 9.5 months median survival observed in patients who received only a targeted therapy called regorafenib.

These experimental drugs, developed by Arcus Biosciences, work by activating the immune system to target and fight cancer cells. Dr. Zev Wainberg, the study’s lead author and co-director of the UCLA Health GI Oncology Program, expressed optimism, stating, “These results pave the way for further exploration of this promising treatment approach.”

Understanding the Statistics and the Trial Design

The American Cancer Society estimates that around 106,590 new cases of colon cancer will be diagnosed in 2024, with approximately 53,010 deaths. Colon cancer remains a leading cause of cancer-related deaths, making early detection and effective treatment options vital. The trial focused on 112 patients who had already undergone previous chemotherapy regimens for metastatic colorectal cancer.

Participants were randomly assigned to two groups. One group received the combination therapy (etrumadenant, zimberelimab, and standard chemotherapy mFOLFOX-6 plus bevacizumab), while the other received only regorafenib. Regorafenib is a cancer growth blocker that works by disrupting signals cancer cells need to grow and form new blood vessels.

Key Findings: Survival and Progression

The results were striking: the combination therapy nearly doubled overall survival times compared to regorafenib alone. Furthermore, it significantly improved “progression-free survival” – the time patients live without their cancer growing. This metric showed 6.2 months for the combo treatment versus 2.1 months for the targeted therapy group alone.

Tumor shrinkage was also more pronounced in the combination therapy group, with partial or complete tumor shrinkage observed in 17.3% of patients, compared to just 2.7% in the regorafenib-only group. The side effects of the novel combination were reported as acceptable and comparable to standard chemotherapy.

These findings, set to be presented at the American Society of Clinical Oncology meeting, underscore the critical role of clinical trials, especially for Black Americans who are disproportionately affected by colon cancer. Participation in such trials is imperative for developing treatments that effectively address the needs of diverse patient populations.